ERROR: Macro njDefaultArticleHeader is missing!

Grapevine

EDA’s emergency management

Back to Top Comments Email Print

Latest News

Caligor names CEO, chief commercial officer

By Emily Bader
March 1, 2017 01:48 PM

Secaucus-based Caligor Opco LLC announced Wednesday that David Edwards has joined the company as CEO. The company has also named Tammy Bishop to the new role of chief commercial officer. CONTINUE READING

Marcus & Millichap announce sale of $3.13M apartment complex in North Bergen

By Emily Bader
March 1, 2017 11:15 AM

Marcus & Millichap announced Wednesday the $3.13 million sale of Riverview Lofts, an apartment property in North Bergen, according to Brian C. Hosey, regional manager of the firm's New Jersey office. CONTINUE READING

advertisement

1st Constitution Bank Names SVP, commercial lending officer

By Emily Bader
March 1, 2017 11:22 AM

1st Constitution Bank announced recently it has appointed Lisa Borghese as senior vice president and commercial lending officer. CONTINUE READING

Asian Food Markets selects R.J. Brunelli as its new tenant representative

By Emily Bader
March 1, 2017 01:12 PM

R.J. Brunelli & Co. LLC has been selected by Asian Food Markets as its new tenant representative for sites in New Jersey, New York and Pennsylvania. CONTINUE READING

Continuum taps 2 new hires for business and market development

By Emily Bader
February 28, 2017 01:24 PM

Continuum Health Alliance, a physician enablement company based in Marlton, announced Tuesday it has hired two new executives to develop its business services and market needs. CONTINUE READING

Roseland details flurry of activity as 2016 ends and 2017 begins

By Mario Marroquin
February 28, 2017 11:07 AM

Roseland Realty Trust closed out 2016 and has started the new year with some major activity, parent Mack-Cali Realty Corp. announced in a news release detailing some of the projects. CONTINUE READING

Metal manufacturer, whose owner died in 2016, is closing; 200 to lose jobs

By Meg Fry
February 28, 2017 01:00 PM

Crowne Architectural Systems in North Bergen will terminate its operations due to cash flow shortage and leave 200 employees without jobs, according to a federal WARN notice. CONTINUE READING

advertisement

With a long-delayed incentives overhaul on its way to becoming law, the state is rolling out emergency guidelines to open itself for business under the new programs, sources said.

One person said the Economic Development Authority could start accepting applications for the new incentives as soon as October, assuming Chris Christie signs the Economic Opportunity Act into law as expected. To do so, a source said, the agency is expected to adopt temporary regulations and formalize them at a later time.

The move would allow many firms and developers to break their holding patterns of the past several months, as they waited on lawmakers and administration officials who wrangled over the high-stakes bill. But the lengthy delay also has allowed the EDA to prepare for a wave of applications, a source said.

The person said the normal process of adopting regulations “just takes time, and there would be a significant void if they went with that process,” because big-ticket incentives like the Urban Transit Hub and Grow New Jersey tax credits are running on empty.

Sale of Ortho sensible for J&J

Speculation has resurfaced that Johnson & Johnson is looking sell its blood-test division, Ortho Clinical Diagnostics, by the end of the year.

Sources following the pharma industry say such a move make sense because blood tests tend to be a low-tech, lower-margin business, offering less returns than newer categories of tests, such as molecular diagnostics, which examine genes.

“This is not a high-margin business,” one source said of blood tests. “It does not add to return on investment. Why do low ROI? It makes no sense. Twenty years ago, you could, because no one else was doing it. But now smaller companies are doing it at lower cost.”

The Wall Street Journal has reported J&J is talking to other health care companies and private equity investors. The New Brunswick-based company isn't talking now, though CEO Alex Gorsky in January said the company was considering divesting the asset as it  focuses more on higher growth drivers. 

Gorsky has said the blood-testing unit may be a better fit as part of another company, or as a standalone company.

Grapevine reports on the behind-the-scenes buzz in the business community. Contact Editor Tom Bergeron at tomb@njbiz.com.

Share This Story On:

EDA’s emergency management

Back to Top Comments Email Print

Latest News

advertisement

With a long-delayed incentives overhaul on its way to becoming law, the state is rolling out emergency guidelines to open itself for business under the new programs, sources said.

One person said the Economic Development Authority could start accepting applications for the new incentives as soon as October, assuming Chris Christie signs the Economic Opportunity Act into law as expected. To do so, a source said, the agency is expected to adopt temporary regulations and formalize them at a later time.

The move would allow many firms and developers to break their holding patterns of the past several months, as they waited on lawmakers and administration officials who wrangled over the high-stakes bill. But the lengthy delay also has allowed the EDA to prepare for a wave of applications, a source said.

The person said the normal process of adopting regulations “just takes time, and there would be a significant void if they went with that process,” because big-ticket incentives like the Urban Transit Hub and Grow New Jersey tax credits are running on empty.

Sale of Ortho sensible for J&J

Speculation has resurfaced that Johnson & Johnson is looking sell its blood-test division, Ortho Clinical Diagnostics, by the end of the year.

Sources following the pharma industry say such a move make sense because blood tests tend to be a low-tech, lower-margin business, offering less returns than newer categories of tests, such as molecular diagnostics, which examine genes.

“This is not a high-margin business,” one source said of blood tests. “It does not add to return on investment. Why do low ROI? It makes no sense. Twenty years ago, you could, because no one else was doing it. But now smaller companies are doing it at lower cost.”

The Wall Street Journal has reported J&J is talking to other health care companies and private equity investors. The New Brunswick-based company isn't talking now, though CEO Alex Gorsky in January said the company was considering divesting the asset as it  focuses more on higher growth drivers. 

Gorsky has said the blood-testing unit may be a better fit as part of another company, or as a standalone company.

Grapevine reports on the behind-the-scenes buzz in the business community. Contact Editor Tom Bergeron at tomb@njbiz.com.

Share This Story On:
advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy
advertisement
ERROR: Macro defaultSidebar is missing!
ERROR: Macro footer_top is missing!
Back to Top